Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biond Biologics
Biotech
Sanofi passes $125M ILT2 asset back to Biond Biologics
Sanofi is handing back the tumor candidate after initiating a phase 2 trial of the anti-ITL2 monoclonal antibody.
Zoey Becker
Mar 3, 2025 11:00am
JPM, Day 2: Sanofi continues deal spree, BI's dark antigen pact
Jan 12, 2021 9:05am
Sanofi pays $125M to take lead in new checkpoint inhibitor space
Jan 12, 2021 8:15am
